Dabigatran Etexilate vs Enoxaparin in Prevention of Venous Thromboembolism (VTE) Post Total Knee Replacement
A Phase III, Randomized, Parallel-group, Double-blind, Active Controlled Study to Investigate the Efficacy and Safety of Two Different Dose Regimens (75mg Day 1 Followed by 150 mg Day 2-completion, and 110 mg Day 1 Followed by 220 mg Day 2-completion) of Dabigatran Etexilate Administered Orally (Capsules), Compared to Enoxaparin 30 mg Twice a Day Subcutaneous for 12 - 15 Days in Prevention of Venous Thromboembolism in Patients With Primary Elective Total Knee Replacement Surgery
調査の概要
状態
条件
研究の種類
入学 (実際)
段階
- フェーズ 3
連絡先と場所
研究場所
-
-
Alabama
-
Birmingham、Alabama、アメリカ
- 1160.24.01074 Capstone Clinical Trials, Inc.
-
Northport、Alabama、アメリカ
- 1160.24.01079 West AL Research, Inc
-
-
Arizona
-
Tucson、Arizona、アメリカ
- 1160.24.01047 Tucson Orhtopaedic Institute
-
-
Arkansas
-
Little Rock、Arkansas、アメリカ
- 1160.24.01025 Martin, Bowen, Hefley Knee and Sports
-
Little Rock、Arkansas、アメリカ
- 1160.24.01053 OrthoArkansas, PA
-
Little Rock、Arkansas、アメリカ
- 1160.24.01085 Martin, Bowen, Hefley Knee and Sports
-
-
California
-
Encinitas、California、アメリカ
- 1160.24.01041 Core Orthopedic Medical Center
-
Glendale、California、アメリカ
- 1160.24.01034 Glendale Adventist Medical Center
-
La Jolla、California、アメリカ
- 1160.24.01005 Scripps Clinical Ctr for Orthopedic Rsrch & Educ
-
Long Beach、California、アメリカ
- 1160.24.01077 Long Beach VA Healthcare system
-
Orange、California、アメリカ
- 1160.24.01064 Orthopedic Specialty Institute
-
-
Colorado
-
Aurora、Colorado、アメリカ
- 1160.24.01031 Colorodo Orthopedic Consultants, PC
-
Denver、Colorado、アメリカ
- 1160.24.01027 Advanced Orthopedic and Sports Medicine Specialists, PC
-
Engelwood、Colorado、アメリカ
- 1160.24.01023 Orthopedic Physicians of Colorado, PC
-
-
Florida
-
Bay Pines、Florida、アメリカ
- 1160.24.01020 Bay Pines VA Medical Center
-
Brandon、Florida、アメリカ
- 1160.24.01024 Pulmonary Associates of Brandon Clinical Research
-
Clearwater、Florida、アメリカ
- 1160.24.01030 Alliance Research, Inc.
-
Deland、Florida、アメリカ
- 1160.24.01039 Florida Orthopedic Associates
-
Hollywood、Florida、アメリカ
- 1160.24.01036 Orthopaedic Associates of South Broward, PA
-
Melbourne、Florida、アメリカ
- 1160.24.01010 MIMA Century Research Associates
-
Miami、Florida、アメリカ
- 1160.24.01062 Miami Institute for Joint Reconstruction
-
Orlando、Florida、アメリカ
- 1160.24.01040 Southern Clinical Research Consultants
-
Pensacola、Florida、アメリカ
- 1160.24.01067 Baptist Clinical Research
-
Pinellas Park、Florida、アメリカ
- 1160.24.01001 Boehringer Ingelheim Investigational Site
-
Pinellas Park、Florida、アメリカ
- 1160.24.01017 Boehringer Ingelheim Investigational Site
-
Pinellas Park、Florida、アメリカ
- 1160.24.01019 Boehringer Ingelheim Investigational Site
-
Port Orange、Florida、アメリカ
- 1160.24.01029 Coastal Medical Research
-
Tampa、Florida、アメリカ
- 1160.24.01038 James A. Haley VA Hospital
-
-
Georgia
-
Atlanta、Georgia、アメリカ
- 1160.24.01063 Resurgens Orthopaedics
-
Atlanta、Georgia、アメリカ
- 1160.24.01072 Resurgeons Orthopedics
-
Lawrencville、Georgia、アメリカ
- 1160.24.01056 Southern Orthopaedic Specialists
-
-
Idaho
-
Boise、Idaho、アメリカ
- 1160.24.01028 Intermountain Research Center
-
-
Iowa
-
Des Moines、Iowa、アメリカ
- 1160.24.01022 Iowa Orthopedic Clinic
-
-
Kentucky
-
Lexington、Kentucky、アメリカ
- 1160.24.01008 Bluegrass Orthopedic/Musculoskeletal Research, LLC
-
-
Maryland
-
Baltimore、Maryland、アメリカ
- 1160.24.01070 Sinai Hospital of Baltimore
-
Towson、Maryland、アメリカ
- 1160.24.01007 Ortho Associates
-
-
Missouri
-
Kansas City、Missouri、アメリカ
- 1160.24.01059 Rockhill Orthopaedics
-
-
Montana
-
Missoula、Montana、アメリカ
- 1160.24.01042 Center for Joint Care
-
-
North Carolina
-
Charlotte、North Carolina、アメリカ
- 1160.24.01014 Charlotte Orthopedic Specialists
-
-
Ohio
-
Cincinnati、Ohio、アメリカ
- 1160.24.01035 Wellington Orthopedics and Sports Medicine
-
-
Oklahoma
-
Oklahoma City、Oklahoma、アメリカ
- 1160.24.01006 VA Medical Center
-
Tulsa、Oklahoma、アメリカ
- 1160.24.01044 Tulsa Bone and Joint Associates
-
-
Oregon
-
Bend、Oregon、アメリカ
- 1160.24.01002 The Orthopedic and Neurological Center of the Cascades
-
-
Pennsylvania
-
Philadelphia、Pennsylvania、アメリカ
- 1160.24.01046 Boehringer Ingelheim Investigational Site
-
-
South Carolina
-
Charleston、South Carolina、アメリカ
- 1160.24.01016
-
Conway、South Carolina、アメリカ
- 1160.24.01073 Coastal Orthopedic Associates, PA
-
-
Texas
-
Austin、Texas、アメリカ
- 1160.24.01032 Seton Medical Center
-
Dallas、Texas、アメリカ
- 1160.24.01003 Texas Orthopedic Associates
-
Dallas、Texas、アメリカ
- 1160.24.01090 VA Medical Center
-
Houston、Texas、アメリカ
- 1160.24.01026 James Muntz, MD
-
Houston、Texas、アメリカ
- 1160.24.01033 Bone and Joint Clinic of Houston
-
Houston、Texas、アメリカ
- 1160.24.01076 Discovery Alliance
-
Lubbock、Texas、アメリカ
- 1160.24.01018 Gill Research Center
-
Plano、Texas、アメリカ
- 1160.24.01069 Correspondence and Pateint vists
-
San Antonio、Texas、アメリカ
- 1160.24.01015 Unlimited Research, LP
-
-
Virginia
-
Alexandria、Virginia、アメリカ
- 1160.24.01012 Anderson Orthopedic Clinic
-
-
Washington
-
Seattle、Washington、アメリカ
- 1160.24.01052 Swedish Medical Center
-
Spokane、Washington、アメリカ
- 1160.24.01057 Orthopedic Specialty Clinic of Spokane, PLLC
-
Tacoma、Washington、アメリカ
- 1160.24.01082 MultiCare Health System
-
-
-
-
-
London、イギリス
- 1160.24.44001 Ravenscourt Park Hospital
-
-
-
-
Alberta
-
Edmonton、Alberta、カナダ
- 1160.24.02031 University of Alberta Hospital
-
Edmonton、Alberta、カナダ
- 1160.24.02036 2B2.37 Walter Mackenizie Centre
-
Red Deer、Alberta、カナダ
- 1160.24.02024 Red Deer Regional Hospital
-
-
British Columbia
-
Kelowna、British Columbia、カナダ
- 1160.24.02032 Kelowna General Hospital
-
Vancouver、British Columbia、カナダ
- 1160.24.02034 Hematology/Oncology Research
-
-
Manitoba
-
Winnipeg、Manitoba、カナダ
- 1160.24.02025 Grace General Hospital
-
-
New Brunswick
-
Fredericton、New Brunswick、カナダ
- 1160.24.02007 Orthopaedics 4NE
-
Saint John、New Brunswick、カナダ
- 1160.24.02027 Atlantic Health Sciences Corporation
-
-
Ontario
-
Ajax、Ontario、カナダ
- 1160.24.02021 Rouge Valley Health System
-
Barrie、Ontario、カナダ
- 1160.24.02008 Orthopaedic Surgery
-
Brantford、Ontario、カナダ
- 1160.24.02016 Orthopaedic Surgery
-
Burlington、Ontario、カナダ
- 1160.24.02010 Joseph Brant Memorial Hospital
-
Guelph、Ontario、カナダ
- 1160.24.02001 73 Delhi Street
-
Hamilton、Ontario、カナダ
- 1160.24.02014 565 Sanatorium Road
-
Kitchener、Ontario、カナダ
- 1160.24.02004 Grand River Hospital
-
Niagara Falls、Ontario、カナダ
- 1160.24.02028 NHS- Greater Niagara General Site
-
Oshawa、Ontario、カナダ
- 1160.24.02022 Lakeridge Health Oshawa
-
Ottawa、Ontario、カナダ
- 1160.24.02017 1053 Carling Avenue
-
Ottawa、Ontario、カナダ
- 1160.24.02026 Ottawa Hospital - General Campus
-
Richmond Hill、Ontario、カナダ
- 1160.24.02015 York Central Hospital Research
-
Scarborough、Ontario、カナダ
- 1160.24.02009 2863 Ellesmere Road
-
St. Catherine's、Ontario、カナダ
- 1160.24.02029 Niagara Health System St. Catharine's General Site
-
Stratford、Ontario、カナダ
- 1160.24.02003 46 General Hospital Drive
-
Thunder Bay、Ontario、カナダ
- 1160.24.02033 Thunder Bay Regional Hospital
-
Toronto、Ontario、カナダ
- 1160.24.02002 Toronto East General Hospital Fracture Clinic
-
Toronto、Ontario、カナダ
- 1160.24.02023 North York General Hospital
-
Toronto、Ontario、カナダ
- 1160.24.02030 St. Joseph's Health Centre
-
Welland、Ontario、カナダ
- 1160.24.02006 206-477 King Street
-
Weston、Ontario、カナダ
- 1160.24.02035 Humber River Regional Hospital
-
Windsor、Ontario、カナダ
- 1160.24.02011 Windsor Regional Hospital
-
Windsor、Ontario、カナダ
- 1160.24.02012 Hotel Dieu Grace Hospital
-
-
Prince Edward Island
-
Charlottetown、Prince Edward Island、カナダ
- 1160.24.02013 Queen Elizabeth Hospital
-
-
-
-
-
Guadalajara, Jalisco、メキシコ
- 1160.24.05009 Traumatologia, Planta Baja
-
México、メキシコ
- 1160.24.05004
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion criteria INCLUSION CRITERIA
- Patients scheduled to undergo a primary, unilateral elective total knee repla cement.
- Male or female 18 years of age or older.
- Patients weighing at least 40 kg.
- Written informed consent prior to the start of study participation.
Exclusion criteria EXCLUSION CRITERIA
- History of bleeding diathesis.
- Constitutional or acquired coagulation disorders that in the investigator's judgment puts the patient at excessive risk for bleeding.
- Major surgery or trauma (e.g. hip fracture) within the last 3 months.
- Recent unstable cardiovascular disease, such as uncontrolled hypertension at the time of enrollment (investigator's judgment) or history of myocardial infarction within the last 3 months.
Spinal or epidural anesthesia, for which more than 3 attempts (sticks) at placement were made, or the placement was traumatic.
Please note that patients, who are not excluded under this criterion, are to have the catheter pulled at the completion of surgery.
- Any history of hemorrhagic stroke or any of the following intracranial pathologies: bleeding, neoplasm, arteriovenous (AV) malformation or aneurysm.
- History of VTE or pre-existing condition requiring anticoagulant therapy.
- Clinically relevant bleeding (e.g. gastrointestinal, pulmonary, intraocular or urogenital bleeding) within the last 6 months.
- Gastric or duodenal ulcer within the last 6 months.
- Liver disease expected to have any potential impact on survival (e.g. hepatitis B or C, cirrhosis, but not Gilbert's syndrome or hepatitis A with complete recovery).
- Elevated AST or ALT >2x upper limit of normal, based on central lab results or local lab results within 1 month before enrollment.
- Known severe renal insufficiency (CrCl < 30 mL/min). In order to determine patient inclusion/exclusion, creatinine clearance (CrCl) needs to be calculated only if serum creatinine is elevated or renal insufficiency is suspected.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:防止
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:ダブル
武器と介入
参加者グループ / アーム |
介入・治療 |
---|---|
実験的:Dabigatran Dose 1
low dose regimen taken once daily
|
low dose regimen taken once daily
low dose regimen taken once daily
|
実験的:Dabigatran Dose 2
high dose regimen taken once daily
|
high dose regimen taken once daily
high dose regimen taken once daily
|
アクティブコンパレータ:Enoxaparin
30 mg subcutaneously twice daily
|
30 mg subcutaneously twice daily
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
---|---|---|
Number of Participants With Total Venous Thromboembolic Event and All-cause Mortality During Treatment Period
時間枠:First administration until 12-15 days
|
Total Venous Thromboembolic Event (VTE) includes both proximal and distal deep vein thrombosis (DVT) (detected by routine bilateral venography), symptomatic DVT (confirmed by venous compression ultrasound, venography or autopsy) and pulmonary embolism (PE) (confirmed by pulmonary V-Q scintigraphy, chest x-ray, pulmonary angiography, spiral CT or autopsy). All of these components and all deaths were centrally adjudicated by the VTE events committee, which was not aware of the treatment allocation of the patients. |
First administration until 12-15 days
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
---|---|---|
Number of Participants With Major Venous Thromboembolic Event and Venous Thromboembolic Event-related Mortality During Treatment Period
時間枠:First administration until 12-15 days
|
Major Venous Thromboembolic Event (VTE) is defined as proximal DVT and PE, as adjudicated by the VTE events committee
|
First administration until 12-15 days
|
Number of Participants With Proximal Deep Vein Thrombosis During Treatment Period
時間枠:First administration until 12-15 days
|
Proximal Deep Vein Thrombosis as adjudicated by the VTE events committee
|
First administration until 12-15 days
|
Number of Participants With Total Deep Vein Thrombosis During Treatment Period
時間枠:First administration until 12-15 days
|
Total Deep Vein Thrombosis as adjudicated by the VTE events committee
|
First administration until 12-15 days
|
Number of Participants With Symptomatic Deep Vein Thrombosis During Treatment Period
時間枠:First administration until 12-15 days
|
Symptomatic Deep Vein Thrombosis, confirmed by venous compression ultrasound, venography or autopsy, and as adjudicated by the VTE events committee
|
First administration until 12-15 days
|
Number of Participants With Pulmonary Embolism During Treatment Period
時間枠:First administration until 12-15 days
|
Pulmonary embolism confirmed by pulmonary V-Q scintigraphy, chest x-ray, pulmonary angiography, spiral CT or autopsy, and as adjudicated by the VTE events committee
|
First administration until 12-15 days
|
Number of Participants Who Died During Treatment Period
時間枠:First administration until 12-15 days
|
All cause death, as adjudicated by the VTE events committee
|
First administration until 12-15 days
|
Number of Participants With Total Venous Thromboembolic Event (VTE) and All-cause Mortality During the Follow-up Period
時間枠:3 months
|
Total Venous Thromboembolic Event (VTE) includes both proximal and distal deep vein thrombosis (DVT) (detected by routine bilateral venography), symptomatic DVT (confirmed by venous compression ultrasound, venography or autopsy) and pulmonary embolism (PE) (confirmed by pulmonary V-Q scintigraphy, chest x-ray, pulmonary angiography, spiral CT or autopsy).
|
3 months
|
Number of Participants With Bleeding Events (Defined According to Modified McMaster Criteria) During Treatment Period
時間枠:First administration until 12-15 days
|
Major bleeding events were defined as
Clinically-relevant was defined as
Minor bleeding events were defined as all other bleeding events that did not fulfil the criteria from above. |
First administration until 12-15 days
|
協力者と研究者
スポンサー
出版物と役立つリンク
便利なリンク
研究記録日
主要日程の研究
研究開始
一次修了 (実際)
研究の完了
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
学習記録の更新
投稿された最後の更新 (見積もり)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。
Dabigatran Dose 1 - day 2 to completionの臨床試験
-
Reistone Biopharma Company Limited完了
-
Hospices Civils de Lyonわからない